
News from Proscia
We’ve assigned a media bias rating of unknown to Proscia. You can read more about our methodology here.
We’ve assigned a rating of Unknown factuality to Proscia. You can read more about how we’ve determined Proscia’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Proscia News

Cancer · Hong KongHONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or…See the Story
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
95% Center coverage: 21 sources
Q&A: Engineering Excellence—How Concentriq LS Delivers a New Standard for Enterprise-Scale Performance
New in Concentriq Streamlined Consults, Personalized Worklists, Expanded DICOM Support, and More
Cheers to USCAP 2025: Recapping The Momentum, Insights, and Inspiration
You've scrolled to the bottom of the feed, there are no more stories.